Welcome To Mylan Inc.

A Legacy You Can Count On

Mylan is the third largest generics and speciality pharmaceutical company in the world. We hold top-five positions in 13 different established markets worldwide and are building a strong presence in many emerging generics markets.

Today, we market more than 900 separate products to consumers in more than 140 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. We also have the deepest pipeline and largest number of products pending regulatory approval in company history.

At Mylan, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide-ranging issues – from complex research, development and regulatory conditions to rapidly changing consumer demands.

Whether we’re improving the health of patients worldwide or meeting the diverse needs of our customers, Mylan delivers. Every time, all the time.

11/18/2009 - Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association... (more)
11/12/2009 - Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier... (more)
11/10/2009 - Mylan Receives FDA Approval for Generic Version of Prevacid® Through its Subsidiary Matrix Laboratories... (more)
10/29/2009 - Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32... (more)
10/26/2009 - Dey Launches and Unveils Next-Generation, Needle-Protected EpiPen(R) (Epinephrine) Auto-Injector with Enhanced Patient-Friendly Features... (more)
Legal and Copyright Disclaimer © Copyright 2009 Mylan Inc. All rights reserved. Privacy Policy